Stay updated on Entinostat + Pembrolizumab in Lymphomas Clinical Trial

Sign up to get notified when there's something new on the Entinostat + Pembrolizumab in Lymphomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Entinostat + Pembrolizumab in Lymphomas Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the study details related to a Phase II study of Pembrolizumab and Entinostat in Patients With Relapsed and Refractory Lymphomas. This change may reflect new information on the effects and outcomes of the combination therapy being tested for treating lymphoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:18:23.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    52%
    Check dated 2024-05-22T20:54:44.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:18:39.000Z thumbnail image

Stay in the know with updates to Entinostat + Pembrolizumab in Lymphomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Entinostat + Pembrolizumab in Lymphomas Clinical Trial page.